MD Anderson Research Highlights for October 2, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Study offers insights into molecular drivers of brain metastases from breast cancer cells
Brain...
MD Anderson Research Highlights for May 8, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
MD Anderson Research Highlights for July 19, 2023
HOUSTON ― The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research...
Adagrasib effective for patients with KRAS G12C-mutant lung cancer and untreated brain metastases
Researchers from The University of Texas MD Anderson Cancer Center found the KRAS G12C inhibitor adagrasib showed promising activity suppressing cancer growth not only within the lungs but also in brain metastases for patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC).
Findings from the Phase Ib cohort of the KRYSTAL-1 trial, published today in the Journal of Clinical Oncology, represent the first prospective...
AACR: Single-cell study uncovers distinct immunosuppressive tumor microenvironment in brain metastases from kidney cancer
ABSTRACT: 5788
In a new study, researchers from The University of Texas MD Anderson Cancer Center created the largest single-cell atlas...
MD Anderson Research Highlights for August 24, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
MD Anderson Research Highlights for June 29, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
MD Anderson Research Highlights for May 18, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
Stereotactic radiosurgery recommended for patients with more than three brain metastases
Researchers from The University of Texas MD Anderson Cancer Center have conducted the first randomized clinical trial comparing stereotactic...
MD Anderson and Taiho Pharmaceutical announce collaboration to accelerate development of novel therapies for brain metastasis and other unmet medical needs
The University of Texas MD Anderson Cancer Center and Taiho Pharmaceutical Co., Ltd., today announced a three-year strategic collaboration...